Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival

  • Taberna, Miren
  • Mena, Marisa
  • Tous, Sara
  • Pavón, Miquel Ángel
  • Oliva, Marc
  • León, Xavier
  • García, Jacinto
  • Guix Arnau, Marta, 1974-
  • Hijano Esque, Rafael
  • Bonfill, Teresa
  • Aguilà, Antón
  • Alemany, Laia
  • Mesía, Ricard
BACKGROUND: Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8th edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. MATERIAL AND METHODS: The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7th edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16INK4a or HPV-mRNA), p16INK4a positivity alone or the combination of HPV-DNA/p16INK4a positivity as diagnostic tests. RESULTS: A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16INK4a or HPV-mRNA), 83 (10.5%) were p16INK4a positive and 58 (7.4%) were double positive for HPV-DNA/p16INK4a. ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16INK4a-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. CONCLUSION: HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients' survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials., This work was partially supported by grants from the Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe (PI14/01819, PI15/00500 and PI11/02096); Ayudas Merck Serono-Fundación Salud 2000 de investigación 2015; Agéncia de Gestió d’Ajuts Universitaris i de Recerca, AGAUR (2017SGR1085 and 2017SGR1718), European Commission 7th Framework Programme COHEAHR (Health-F3-2013-603019) and Rio Hortega-SEOM (ISCIII-Spanish Society of Medical Oncology) (personal grant to MT). The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study

  • Trapero-Bertran, Marta
  • Acera, Amelia
  • de Sanjosé, Silvia
  • Manresa, Josep Maria
  • Rodríguez, Diego
  • Rodriguez, Ana
  • Bonet, Josep Maria
  • Sanchez, Norman
  • Hidalgo, Pablo
  • Díaz Sanchis, Mireia
Background. The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Methods. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years – the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. Results. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. Conclusions. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women., This project was financed by the Spanish Ministry of Health (ISCIII Exp. PI10/01275) in the 2010 grant call of the Strategic Health Action Plan within the framework of the National Plan for Scientific Research, Development, and Innovative Technology. It was co-financed by the European Union through European Funds for Regional Development (FEDER). Partial support for the development of this work was received from Spanish public grants from the Instituto de Salud Carlos III (RTIC RD06/0020/0095, RD12/0036/0056, and CIBERESP) and from the Agència de Gestió d’Ajuts Universitaris i de Recerca (grants AGAUR 2014SGR1077 and 2014SGR2016). MD and SdS were partially supported by grants from the Spanish Government via the Instituto de Salud Carlos III-ISCIII cofunded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe [PI11/02090, PI14/01219, PI16/01254, CIBERESP CB06/02/0073 and CB16/12/00401, and the Spanish Cancer Network RTICC RD12/0036/0056], the European Commission via the 7th Framework Program [CoheaHr Project 603019], the Government of Catalonia via the Agència de Gestió d'Ajuts Universitaris i de Recerca [2014SGR1077 and 2014SGR756] and from Recercaixa [MD088652].
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis

  • Mena Cervigón, Marisa
  • Taberna, Miren
  • Monfil, Laura
  • Arbyn, Marc
  • Sanjosé Llongueras, Silvia de
  • Bosch José, Francesc Xavier, 1947-
  • Alemany i Vilches, Laia
  • Bruni, Laia
Background. Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in depth. Methods. A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and population type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations were assessed by the Spearman test. Results. Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% globally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV infection. The age-specific HPV distribution revealed a prevalence of >= 5% over 40 years of age and a lower prevalence at younger ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV in healthy women, or tobacco use. Conclusions. Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infection across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review

  • Gallagher, K. E.
  • Kadokura, E.
  • Eckert, Linda O.
  • Miyake, S.
  • Mounier-Jack, S.
  • Aldea, Marta
  • Ross, D. A.
  • Watson-Jones, Deborah
Background: Completion of multiple dose vaccine schedules is crucial to ensure a protective immune response, and maximise vaccine cost-effectiveness. While barriers and facilitators to vaccine uptake have recently been reviewed, there is no comprehensive review of factors influencing subsequent adherence or completion, which is key to achieving vaccine effectiveness. This study identifies and summarises the literature on factors affecting completion of multi-dose vaccine schedules by adolescents. Methods: Ten online databases and four websites were searched (February 2014). Studies with analysis of factors predicting completion of multi-dose vaccines were included. Study participants within 9-19 years of age were included in the review. The defined outcome was completion of the vaccine series within 1 year among those who received the first dose. Results: Overall, 6159 abstracts were screened, and 502 full texts were reviewed. Sixty one studies were eligible for this review. All except two were set in high-income countries. Included studies evaluated human papillomavirus vaccine, hepatitis A, hepatitis B, and varicella vaccines. Reported vaccine completion rates, among those who initiated vaccination, ranged from 27 % to over 90 %. Minority racial or ethnic groups and inadequate health insurance coverage were risk factors for low completion, irrespective of initiation rates. Parental healthcare seeking behaviour was positively associated with completion. Vaccine delivery in schools was associated with higher completion than delivery in the community or health facilities. Gender, prior healthcare use and socio-economic status rarely remained significant risks or protective factors in multivariate analysis. Conclusions: Almost all studies investigating factors affecting completion have been carried out in developed countries and investigate a limited range of variables. Increased understanding of barriers to completion in adolescents will be invaluable to future new vaccine introductions and the further development of an adolescent health platform.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer

  • Moriña, David
  • Martí-Gil, José Ignacio
  • Puig i Casado, Pere
  • Diaz Sanchis, Mireia
Background: Most cost-effectiveness analyses in the context of cervical cancer prevention involve the use of mathematical models to simulate HPV infection, cervical disease and prevention strategies. However, it is common for professionals who would need to perform these analyses to not be familiar with the models. This work introduces the Online Cost-Effectiveness ANalysis tool, featuring an easy-to-use web interface providing health professionals, researchers and decision makers involved in cervical cancer prevention programmes with a useful instrument to conduct complex cost-effectiveness analyses, which are becoming an essential tool as an approach for supporting decision-making that involves important trade-offs. Results: The users can run cost-effectiveness evaluations of cervical cancer prevention strategies without deep knowledge of the underlying mathematical model or any programming language, obtaining the most relevant costs and health outcomes in a user-friendly format. The results provided by the tool are consistent with the existing literature. Conclusions: Having such a tool will be an asset to the cervical cancer prevention community, providing researchers with an easy-to-use instrument to conduct cost-effectiveness analyses. Keywords: Cervical cancer screening, Markov chain model, Cost-effectiveness, Online tool, cancer prevention, Decision making
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Underscreened Women Remain Overrepresented In The Pool Of Cervical Cancer Cases In Spain: A Need To Rethink The Screening Interventions

  • Ibáñez, Raquel
  • Alejo, Maria
  • Combalia, Neus
  • Tarroch, Xavier
  • Autonell, Josefina
  • Codina, Laia
  • Culubret, Montserrat
  • Bosch José, Francesc Xavier, 1947-
  • Sanjosé Llongueras, Silvia de
Objective. Audit of women with invasive cervical cancer (CC) is critical for quality control within screening activities. We analysed the screening history in the 10 years preceding the study entry in women with and without CC during 2000-2011. Methods. 323 women with CC from six pathology departments in Catalonia (Spain) and 23,782 women with negative cytology were compared. Age, previous history of cytologies, and histological type and FIGO stage were collected from the pathology registries. Logistic regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CI95%). Results. History of cytology was registered in 26.2% of CC cases and in 78% of the control women (P < 0.0001) and its frequency decreased with increasing age. Compared to women with squamous cell carcinoma, adenocarcinoma cases were significantly more likely to have a cytology within the 3-year interval preceding cancer diagnosis (OR = 2.6 CI 95%: 1.2-5.6) and to have normal cytology results in previous screenings (OR = 2.4 CI 95%: 1.2-4.5). FIGO II-IV cases were more common among older women (older than 60 years). Conclusions. Absence of prior screening history was extremely common among CC cases compared to controls. Organized actions to reduce underscreened women and use of highly sensitive HPV-based tests could be important to reduce CC burden.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Hpv-relatedness Definitions For Classifying Hpv-related Oropharyngeal Cancer Patient Do Impact On Tnm Classification And Patients' Survival

  • Taberna, Miren
  • Mena Cervigón, Marisa
  • Tous, Sara
  • Pavón Ribas, Miquel Àngel
  • Oliva, Marc
  • León, Xavier
  • Garcia, Jacinto
  • Guix, Marta
  • Hijano, Rafael
  • Bonfill, Teresa
  • Aguilà, Anton
  • Alemany i Vilches, Laia
  • Mesía Nin, Ricard
Background Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8 th edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. Material and methods The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7 th edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16(INK4a) or HPV-mRNA), p16(INK4a) positivity alone or the combination of HPV-DNA/p16(INK4a) positivity as diagnostic tests. Results A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16(INK4a) or HPV-mRNA), 83 (10.5%) were p16(INK4a) positive and 58 (7.4%) were double positive for HPV-DNA/p16(INK4a). ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16(INK4a)-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. Conclusion HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients' survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Moving towards an organized cervical cancer screening: costs and impact

  • Diaz Sanchis, Mireia
  • Moriña, David
  • Rodríguez Salés, Vanesa
  • Ibáñez, Raquel
  • Espinàs Piñol, Josep Alfons
  • Sanjosé Llongueras, Silvia de
Background: HPV screening has been shown to be more cost-effective than cytology screening under most scenarios. Furthermore, it should be offered only in organized programmes with good quality assurance mechanisms. This study analyses the comparative cost of the current policy of opportunistic cytology screening vs. a hypothetical organized programme based on primary HPV screening. Methods: Total cervical cancer expenditure was defined as the sum of three cost elements: (i) direct (medical and non-medical) costs, obtained from a calibrated Markov model of the natural history of HPV and cervical cancer; (ii) programmatic costs, estimated based on other organized screening programmes; and (iii) indirect costs, extrapolated from previously published data. Results: Organized HPV screening at 5-year intervals costs consistently less across all coverage levels than opportunistic cytology screening at 3-year intervals. The current annual direct medical cost to the public health system of the opportunistic cytology at 40% coverage is estimated at (sic)33.2 per woman screened aged 25-64. Under an organized programme of primary HPV screening at 70% coverage, the cost is estimated to be (sic)18.4 per woman screened aged 25-64. Conclusion: Our study concludes that the economic resources currently devoted to providing opportunistic cytology screening to 40% of the target population at 3-year intervals could be more effectively used to screen 70% of the target population at 5-year intervals by switching to an organized programme based on primary HPV screening. This finding is of relevance to other European countries or regions with similar screening policies and health infrastructures.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention

  • Moriña, David
  • Sanjosé Llongueras, Silvia de
  • Diaz Sanchis, Mireia
Markov chain models are commonly used to simulate the natural history of human papillomavirus infection and subsequent cervical lesions with the aim of predicting future benefits of health interventions. Developing and calibrating these models entails making a number of critical decisions that will influence the ability of the model to reflect real conditions and predict future situations. Accuracy of selected inputs and calibration procedures are two of the crucial aspects for model performance and understanding their influence is essential, especially when involves policy decisions. The aim of this work is to assess the health and economic impact on cervical cancer prevention strategies currently under discussion according to the most common methods of model calibration combined with different accuracy degree of initial inputs. Model results show large differences on the goodness of fit and cost-effectiveness outcomes depending on the calibration approach used, and these variations may affect health policy decisions. Our findings strengthen the importance of obtaining good calibrated probability matrices to get reliable health and cost outcomes, and are directly generalizable to any cost-effectiveness analysis based on Markov chain models.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study

  • Trapero Bertran, Marta
  • Acera Pérez, Amèlia
  • Sanjosé Llongueras, Silvia de
  • Manresa Domínguez, Josep Maria
  • Rodríguez Capriles, Diego
  • Ana Rodriguez Martinez, Ana
  • Bonet Simó, Josep Maria
  • Sanchez Sanchez, Norman
  • Hidalgo Valls, Pablo
  • Diaz Sanchis, Mireia
Background: The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Methods: Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. Results: The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was (sic)2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. Conclusions: In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than (sic)490 for every 1000 women.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study

  • Trapero-Bertran, Marta
  • Acera Perez, Amèlia
  • de Sanjose, Silvia
  • Manresa Domínguez, Josep Maria
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchis, Mireia
This project was financed by the Spanish Ministry of Health (ISCIII Exp. PI10/ 01275) in the 2010 grant call of the Strategic Health Action Plan within the framework of the National Plan for Scientific Research, Development, and Innovative Technology. It was co-financed by the European Union through European Funds for Regional Development (FEDER). Partial support for the development of this work was received from Spanish public grants from the Instituto de Salud Carlos III (RTIC RD06/0020/0095, RD12/0036/0056, and CIBERESP) and from the Agència de Gestió d’Ajuts Universitaris i de Recerca (grants AGAUR 2014SGR1077 and 2014SGR2016). MD and SdS were partially supported by grants from the Spanish Government via the Instituto de Salud Carlos III-ISCIII cofunded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe [PI11/02090, PI14/01219, PI16/01254, CIBERESP CB06/02/0073 and CB16/12/ 00401, and the Spanish Cancer Network RTICC RD12/0036/0056], the European Commission via the 7th Framework Program [CoheaHr Project 603019], the Government of Catalonia via the Agència de Gestió d'Ajuts Universitaris i de Recerca [2014SGR1077 and 2014SGR756] and from Recercaixa [MD088652]., Background: The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Methods: Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years – the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. Results: The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. Conclusions: In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study

  • Trapero Bertran, Marta
  • Acera Pérez, Amèlia
  • Sanjosé Llongueras, Silvia de
  • Manresa Domínguez, Josep Maria
  • Rodríguez Capriles, Diego
  • Ana Rodriguez Martinez, Ana
  • Bonet Simó, Josep Maria
  • Sanchez Sanchez, Norman
  • Hidalgo Valls, Pablo
  • Diaz Sanchis, Mireia
Background: The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Methods: Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. Results: The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was (sic)2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. Conclusions: In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than (sic)490 for every 1000 women.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Moving towards an organized cervical cancer screening: costs and impact

  • Diaz Sanchis, Mireia
  • Moriña, David
  • Rodríguez Salés, Vanesa
  • Ibáñez, Raquel
  • Espinàs Piñol, Josep Alfons
  • Sanjosé Llongueras, Silvia de
Background: HPV screening has been shown to be more cost-effective than cytology screening under most scenarios. Furthermore, it should be offered only in organized programmes with good quality assurance mechanisms. This study analyses the comparative cost of the current policy of opportunistic cytology screening vs. a hypothetical organized programme based on primary HPV screening. Methods: Total cervical cancer expenditure was defined as the sum of three cost elements: (i) direct (medical and non-medical) costs, obtained from a calibrated Markov model of the natural history of HPV and cervical cancer; (ii) programmatic costs, estimated based on other organized screening programmes; and (iii) indirect costs, extrapolated from previously published data. Results: Organized HPV screening at 5-year intervals costs consistently less across all coverage levels than opportunistic cytology screening at 3-year intervals. The current annual direct medical cost to the public health system of the opportunistic cytology at 40% coverage is estimated at (sic)33.2 per woman screened aged 25-64. Under an organized programme of primary HPV screening at 70% coverage, the cost is estimated to be (sic)18.4 per woman screened aged 25-64. Conclusion: Our study concludes that the economic resources currently devoted to providing opportunistic cytology screening to 40% of the target population at 3-year intervals could be more effectively used to screen 70% of the target population at 5-year intervals by switching to an organized programme based on primary HPV screening. This finding is of relevance to other European countries or regions with similar screening policies and health infrastructures.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Underscreened Women Remain Overrepresented In The Pool Of Cervical Cancer Cases In Spain: A Need To Rethink The Screening Interventions

  • Ibáñez, Raquel
  • Alejo, Maria
  • Combalia, Neus
  • Tarroch, Xavier
  • Autonell, Josefina
  • Codina, Laia
  • Culubret, Montserrat
  • Bosch José, Francesc Xavier, 1947-
  • Sanjosé Llongueras, Silvia de
Objective. Audit of women with invasive cervical cancer (CC) is critical for quality control within screening activities. We analysed the screening history in the 10 years preceding the study entry in women with and without CC during 2000-2011. Methods. 323 women with CC from six pathology departments in Catalonia (Spain) and 23,782 women with negative cytology were compared. Age, previous history of cytologies, and histological type and FIGO stage were collected from the pathology registries. Logistic regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CI95%). Results. History of cytology was registered in 26.2% of CC cases and in 78% of the control women (P < 0.0001) and its frequency decreased with increasing age. Compared to women with squamous cell carcinoma, adenocarcinoma cases were significantly more likely to have a cytology within the 3-year interval preceding cancer diagnosis (OR = 2.6 CI 95%: 1.2-5.6) and to have normal cytology results in previous screenings (OR = 2.4 CI 95%: 1.2-4.5). FIGO II-IV cases were more common among older women (older than 60 years). Conclusions. Absence of prior screening history was extremely common among CC cases compared to controls. Organized actions to reduce underscreened women and use of highly sensitive HPV-based tests could be important to reduce CC burden.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention

  • Moriña, David
  • Sanjosé Llongueras, Silvia de
  • Diaz Sanchis, Mireia
Markov chain models are commonly used to simulate the natural history of human papillomavirus infection and subsequent cervical lesions with the aim of predicting future benefits of health interventions. Developing and calibrating these models entails making a number of critical decisions that will influence the ability of the model to reflect real conditions and predict future situations. Accuracy of selected inputs and calibration procedures are two of the crucial aspects for model performance and understanding their influence is essential, especially when involves policy decisions. The aim of this work is to assess the health and economic impact on cervical cancer prevention strategies currently under discussion according to the most common methods of model calibration combined with different accuracy degree of initial inputs. Model results show large differences on the goodness of fit and cost-effectiveness outcomes depending on the calibration approach used, and these variations may affect health policy decisions. Our findings strengthen the importance of obtaining good calibrated probability matrices to get reliable health and cost outcomes, and are directly generalizable to any cost-effectiveness analysis based on Markov chain models.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hpv-relatedness Definitions For Classifying Hpv-related Oropharyngeal Cancer Patient Do Impact On Tnm Classification And Patients' Survival

  • Taberna, Miren
  • Mena Cervigón, Marisa
  • Tous, Sara
  • Pavón Ribas, Miquel Àngel
  • Oliva, Marc
  • León, Xavier
  • Garcia, Jacinto
  • Guix, Marta
  • Hijano, Rafael
  • Bonfill, Teresa
  • Aguilà, Anton
  • Alemany i Vilches, Laia
  • Mesía Nin, Ricard
Background Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8 th edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. Material and methods The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7 th edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16(INK4a) or HPV-mRNA), p16(INK4a) positivity alone or the combination of HPV-DNA/p16(INK4a) positivity as diagnostic tests. Results A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16(INK4a) or HPV-mRNA), 83 (10.5%) were p16(INK4a) positive and 58 (7.4%) were double positive for HPV-DNA/p16(INK4a). ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16(INK4a)-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. Conclusion HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients' survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review

  • Gallagher, K. E.
  • Kadokura, E.
  • Eckert, Linda O.
  • Miyake, S.
  • Mounier-Jack, S.
  • Aldea, Marta
  • Ross, D. A.
  • Watson-Jones, Deborah
Background: Completion of multiple dose vaccine schedules is crucial to ensure a protective immune response, and maximise vaccine cost-effectiveness. While barriers and facilitators to vaccine uptake have recently been reviewed, there is no comprehensive review of factors influencing subsequent adherence or completion, which is key to achieving vaccine effectiveness. This study identifies and summarises the literature on factors affecting completion of multi-dose vaccine schedules by adolescents. Methods: Ten online databases and four websites were searched (February 2014). Studies with analysis of factors predicting completion of multi-dose vaccines were included. Study participants within 9-19 years of age were included in the review. The defined outcome was completion of the vaccine series within 1 year among those who received the first dose. Results: Overall, 6159 abstracts were screened, and 502 full texts were reviewed. Sixty one studies were eligible for this review. All except two were set in high-income countries. Included studies evaluated human papillomavirus vaccine, hepatitis A, hepatitis B, and varicella vaccines. Reported vaccine completion rates, among those who initiated vaccination, ranged from 27 % to over 90 %. Minority racial or ethnic groups and inadequate health insurance coverage were risk factors for low completion, irrespective of initiation rates. Parental healthcare seeking behaviour was positively associated with completion. Vaccine delivery in schools was associated with higher completion than delivery in the community or health facilities. Gender, prior healthcare use and socio-economic status rarely remained significant risks or protective factors in multivariate analysis. Conclusions: Almost all studies investigating factors affecting completion have been carried out in developed countries and investigate a limited range of variables. Increased understanding of barriers to completion in adolescents will be invaluable to future new vaccine introductions and the further development of an adolescent health platform.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival

  • Taberna, Miren
  • Mena, Marisa
  • Tous, Sara
  • Pavón, Miquel Ángel
  • Oliva, Marc
  • León, Xavier
  • García, Jacinto
  • Guix Arnau, Marta, 1974-
  • Hijano Esque, Rafael
  • Bonfill, Teresa
  • Aguilà, Antón
  • Alemany, Laia
  • Mesía, Ricard
BACKGROUND: Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8th edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. MATERIAL AND METHODS: The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7th edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16INK4a or HPV-mRNA), p16INK4a positivity alone or the combination of HPV-DNA/p16INK4a positivity as diagnostic tests. RESULTS: A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16INK4a or HPV-mRNA), 83 (10.5%) were p16INK4a positive and 58 (7.4%) were double positive for HPV-DNA/p16INK4a. ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16INK4a-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. CONCLUSION: HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients' survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials., This work was partially supported by grants from the Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe (PI14/01819, PI15/00500 and PI11/02096); Ayudas Merck Serono-Fundación Salud 2000 de investigación 2015; Agéncia de Gestió d’Ajuts Universitaris i de Recerca, AGAUR (2017SGR1085 and 2017SGR1718), European Commission 7th Framework Programme COHEAHR (Health-F3-2013-603019) and Rio Hortega-SEOM (ISCIII-Spanish Society of Medical Oncology) (personal grant to MT). The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis

  • Mena Cervigón, Marisa
  • Taberna, Miren
  • Monfil, Laura
  • Arbyn, Marc
  • Sanjosé Llongueras, Silvia de
  • Bosch José, Francesc Xavier, 1947-
  • Alemany i Vilches, Laia
  • Bruni, Laia
Background. Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in depth. Methods. A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and population type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations were assessed by the Spearman test. Results. Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% globally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV infection. The age-specific HPV distribution revealed a prevalence of >= 5% over 40 years of age and a lower prevalence at younger ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV in healthy women, or tobacco use. Conclusions. Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infection across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer

  • Moriña, David
  • Martí-Gil, José Ignacio
  • Puig i Casado, Pere
  • Diaz Sanchis, Mireia
Background: Most cost-effectiveness analyses in the context of cervical cancer prevention involve the use of mathematical models to simulate HPV infection, cervical disease and prevention strategies. However, it is common for professionals who would need to perform these analyses to not be familiar with the models. This work introduces the Online Cost-Effectiveness ANalysis tool, featuring an easy-to-use web interface providing health professionals, researchers and decision makers involved in cervical cancer prevention programmes with a useful instrument to conduct complex cost-effectiveness analyses, which are becoming an essential tool as an approach for supporting decision-making that involves important trade-offs. Results: The users can run cost-effectiveness evaluations of cervical cancer prevention strategies without deep knowledge of the underlying mathematical model or any programming language, obtaining the most relevant costs and health outcomes in a user-friendly format. The results provided by the tool are consistent with the existing literature. Conclusions: Having such a tool will be an asset to the cervical cancer prevention community, providing researchers with an easy-to-use instrument to conduct cost-effectiveness analyses. Keywords: Cervical cancer screening, Markov chain model, Cost-effectiveness, Online tool, cancer prevention, Decision making
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study

  • Trapero-Bertran, Marta
  • Acera, Amelia
  • de Sanjosé, Silvia
  • Manresa, Josep Maria
  • Rodríguez, Diego
  • Rodriguez, Ana
  • Bonet, Josep Maria
  • Sanchez, Norman
  • Hidalgo, Pablo
  • Díaz Sanchis, Mireia
Background. The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Methods. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years – the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. Results. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. Conclusions. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women., This project was financed by the Spanish Ministry of Health (ISCIII Exp. PI10/01275) in the 2010 grant call of the Strategic Health Action Plan within the framework of the National Plan for Scientific Research, Development, and Innovative Technology. It was co-financed by the European Union through European Funds for Regional Development (FEDER). Partial support for the development of this work was received from Spanish public grants from the Instituto de Salud Carlos III (RTIC RD06/0020/0095, RD12/0036/0056, and CIBERESP) and from the Agència de Gestió d’Ajuts Universitaris i de Recerca (grants AGAUR 2014SGR1077 and 2014SGR2016). MD and SdS were partially supported by grants from the Spanish Government via the Instituto de Salud Carlos III-ISCIII cofunded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe [PI11/02090, PI14/01219, PI16/01254, CIBERESP CB06/02/0073 and CB16/12/00401, and the Spanish Cancer Network RTICC RD12/0036/0056], the European Commission via the 7th Framework Program [CoheaHr Project 603019], the Government of Catalonia via the Agència de Gestió d'Ajuts Universitaris i de Recerca [2014SGR1077 and 2014SGR756] and from Recercaixa [MD088652].
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain, the CRIVERVA study

  • Trapero Bertrán, Marta
  • Acera Pérez, Amelia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Manresa, J. M|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchís, Mireia
The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women. ClinicalTrials.gov Identifier: . The online version of this article (doi:10.1186/s12889-017-4115-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Online Cost-Effectiveness ANalysis (OCEAN), a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer

  • Moriña, David|||0000-0001-5949-7443
  • Martí, José Ignacio
  • Puig, Pedro|||0000-0002-6607-9642
  • Díaz Sanchís, Mireia
Most cost-effectiveness analyses in the context of cervical cancer prevention involve the use of mathematical models to simulate HPV infection, cervical disease and prevention strategies. However, it is common for professionals who would need to perform these analyses to not be familiar with the models. This work introduces the Online Cost-Effectiveness ANalysis tool, featuring an easy-to-use web interface providing health professionals, researchers and decision makers involved in cervical cancer prevention programmes with a useful instrument to conduct complex cost-effectiveness analyses, which are becoming an essential tool as an approach for supporting decision-making that involves important trade-offs. The users can run cost-effectiveness evaluations of cervical cancer prevention strategies without deep knowledge of the underlying mathematical model or any programming language, obtaining the most relevant costs and health outcomes in a user-friendly format. The results provided by the tool are consistent with the existing literature. Having such a tool will be an asset to the cervical cancer prevention community, providing researchers with an easy-to-use instrument to conduct cost-effectiveness analyses.